Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | FNTA | P49354 | 4/20 | 0.49 |
| ▸ | FNTB | P49356 | 4/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6624185 | 1.00 | ALDH1A1 (0.55) | ALDH1A1MAPTFNTAFNTBTDP1 | |
| SCHEMBL6775900 | 0.88 | FNTA (0.61) | ALDH1A1MAPTFNTAFNTBTDP1 | |
| SCHEMBL6775897 | 0.88 | FNTA (0.61) | ALDH1A1MAPTFNTAFNTBTDP1 | |
| SCHEMBL8584881 | 0.85 | FNTA (0.58) | ALDH1A1MAPTFNTAFNTBTDP1 | |
| SCHEMBL6625988 | 0.85 | FNTA (0.54) | FNTAFNTBTDP1PGGT1B | |
| SCHEMBL6625989 | 0.85 | FNTA (0.54) | FNTAFNTBTDP1PGGT1B | |
| SCHEMBL8365768 | 0.85 | FNTA (0.58) | ALDH1A1MAPTFNTAFNTBTDP1 | |
| SCHEMBL8365497 | 0.83 | FNTA (0.58) | ALDH1A1MAPTFNTAFNTBTDP1 | |
| SCHEMBL8365758 | 0.79 | ALDH1A1 (0.53) | ALDH1A1MAPTFNTAFNTBTDP1 | |
| SCHEMBL6775666 | 0.78 | FNTA (0.59) | ALDH1A1MAPTFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6693123-B2 | (4-(3-PYRIDYLAMINOMETHYLENE)-2-PHENYLBENZOYL)-N -METHYLMETHIONINE, METHYL ESTER FOR EXAMPLE; RESTENOSIS, HYPERPLASIA | UNIVERSITY OF PITTSBURGH | 2004-02-17 | — | — | US | disclosed |
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | UNIVERSITY OF PITTSBURGH (US) | 2002-12-19 | — | — | US | disclosed |
| US-6310095-B1 | INHIBITING OR TREATING CANCER, TREATING INTIMAL HYPERPLASIA ASSOCIATED WITH RESTENOSIS AND ATHEROSCLEROSIS, INHIBITING POST-TRANSLATIONAL MODIFICATION OF ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE AND/OR GERANYLGERANYLTRANSFERASE | UNIVERSITY OF PITTSBURGH | 2001-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | LANCL1, FNTB, DHCR7 | ALDH1A1 1121/4885MAPT 4674/4885FNTA 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.